/**/ document.writeln("\n\n\n\n\n \n\n\n\n\n \n \n \n\n
\n\n \n
\n \n \n \n \n
 Recent News for Halozyme Therapeutics Inc.\n \n\n\n\n\n
Nov 23 7:06 AM EST
\n\n\n\n
\n \n
\n \n \n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n
\n\n Nov 09, 2009 6:03 AM EST
\n\n \n ProMetic and Halozyme Enter Into Long-Term Supply Agreement - Marketwire Canada\n \n \n
\n\n Nov 09, 2009 6:01 AM EST
\n\n \n ProMetic and Halozyme Enter Into Long-Term Supply Agreement - Marketwire\n \n \n
\n\n Nov 06, 2009 9:00 PM EST
\n\n \n Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme - Business Wire\n \n \n
\n\n Nov 06, 2009 7:29 AM EST
\n\n \n Halozyme Therapeutics Reports Third Quarter 2009 Financial Results - Business Wire\n \n \n
\n\n Oct 28, 2009 7:30 AM EDT
\n\n \n Halozyme to Host Third Quarter Conference Call on November 6 and Present at Two Upcoming Investor Conferences - Business Wire\n \n \n
\n\n Oct 22, 2009 1:01 AM EDT
\n\n \n Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R) - Business Wire\n \n \n
\n\n Oct 21, 2009 1:30 PM EDT
\n\n \n Halozyme Study Results Show Faster Insulin Absorption when Administered in Combination with a Wide Range of PH20 Enzyme Concentrations - Business Wire\n \n \n
\n
\n\n");